Market research and business consulting firm Frost & Sullivan announced on Tuesday that Indonesia-based PT Prodia Diacro Laboratories (Prodia the CRO) has received the 2026 Southeast Asian Customer Value Leadership Recognition in the contract research organisation (CRO) industry for its achievements in customer-centric service delivery, integrated clinical research capabilities, and operational excellence.
According to Frost & Sullivan, the recognition highlights Prodia the CRO's ability to deliver measurable customer value while strengthening Indonesia's position in Southeast Asia's evolving clinical research landscape.
Prodia the CRO brings together regulatory consulting, clinical trial management, site management organisation services, central laboratory support, consumer product clinical assessment, and pharmacovigilance capabilities. The integrated model reduces vendor fragmentation, streamlines communication, and enables sponsors to access coordinated support across the clinical research life cycle.
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
Foventa makes key CMO and CFO appointments
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
Teva reports positive Phase 2a data for TEV '408 in celiac disease
Ono Pharma partners with Aitia on neurological disease drug discovery
BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline
AstraZeneca completes global licence agreement for Zegfrovy
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
UCB agrees with US government to lower medicine costs and strengthen US manufacturing